Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vinblastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinblastine SCHEMBL2923482 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL3549 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29357903 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL28131624 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL3550 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL5535862 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29594152 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29554704 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29879166 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL5306718 | 0.99 | MAPT (0.99) | MAPTMEN1KMT2ALMNATUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103965219-A | Vincristine and method for synthesizing vincristine sulfate | HUBEI HONCH PHARMACEUTICAL CO LTD | 2014-08-06 | — | — | CN | claimed |
| EP-3080341-B1 | METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA INC (US) | 2020-02-12 | — | — | EP | disclosed |
| CN-103703174-B | Combination pharmaceutical compositions and uses thereof | 因特利凯有限责任公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-106573036-A | Combination therapy for ameliorating adverse side effects of chemotherapy | 益生生技开发股份有限公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106456624-A | Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system | 生物制药合伙公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106458856-A | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) | 约翰霍普金斯大学 | 2017-02-22 | — | — | CN | disclosed |
| CN-103491962-B | Combinations of kinase inhibitors and uses thereof | 因特利凯有限责任公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-104204804-B | Combinations of kinase inhibitors and uses thereof | 因特利凯有限责任公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-105246482-A | Combinations of kinase inhibitors and uses thereof | INTELLIKINE LLC | 2016-01-13 | — | — | CN | disclosed |
| US-20150160246-A1 | DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-6720337-B2 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxlmic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6656955-B2 | Side effect reduction; synergistic mixture | N-GENE RESEARCH LABORATORIES, INC. | 2003-12-02 | — | — | US | disclosed |
| CN-1127984-C | Pharmaceutical composition containing antitumor drug and hydroximic acid derivative and having antitumor enhancing activity and/or reduced side effect | N GENE RES LAB INC (HU) | 2003-11-19 | — | — | CN | disclosed |
| EP-0993304-B1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N GENE RES LAB INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030050345-A1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2003-03-13 | — | — | US | disclosed |
| US-6440998-B1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2002-08-27 | — | — | US | disclosed |
| CN-1263471-A | Pharmaceutical composition containing antitumor drug and hydroximic acid derivative and having antitumor enhancing activity and/or reduced side effect | N GENE RES LAB INC (US) | 2000-08-16 | — | — | CN | disclosed |
| EP-0993304-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-Gene Research Laboratories Inc. (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998058676-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-GENE RESEARCH LABORATORIES INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| CN-1007958-B | PROCESS FOR THE PREPARATION OF METAL COMPLEXES OF BIS-INDOLE COMPOUNDS AND AGUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RICHTER GEDEON VEGYESZET (HU) | 1990-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050345-A1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDGF, CA7 | TUBB4A 2986/4885TUBB 2891/4885TUBA3C 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.